Prostate Cell News Volume 10.44 | Nov 22 2019

TOP STORY

USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair

In vivo characterization of tumor-associated deubiquitinase USP22 upregulation and unbiased interrogation of USP22-regulated functions in vitro demonstrated critical roles for USP22 in prostate cancer. [Cancer Res] Abstract

(Ranked by impact factor of the journal)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer

In androgen-receptor-expressing prostate cancer cells, CREB5 interactions enhanced androgen-receptor activity at a subset of promoters and enhancers upon enzalutamide treatment, including MYC and genes involved in the cell cycle. [Cell Rep] Full Article | Graphical Abstract

BRF1 Accelerates Prostate Tumorigenesis and Perturbs Immune Infiltration

In vitro studies in human prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation whereas the transient downregulation of BRF1 reduced proliferation and mediated cell cycle arrest. [Oncogene] Full Article

A NF-ĸB-Activin a Signaling Axis Enhances Prostate Cancer Metastasis

To dissect the molecular cues from cancer cell-microenvironment interaction that drive metastatic cascade, bone metastatic prostate cancer cells were intravenously implanted into zebrafish embryos and mice tibia forming metastatic lesions. [Oncogene] Abstract

Circular RNA circFOXO3 Promotes Prostate Cancer Progression through Sponging miR-29a-3p

Researchers found that circFOXO3 was up-regulated in both prostate cancer tissues and serum samples. Moreover, circFOXO3 was positively correlated with the Gleason score in prostate cancer samples. [J Cell Mol Med] Full Article

Regulation of Cell-Cell Adhesion in Prostate Cancer Cells by MicroRNA-96 through Upregulation of E-Cadherin and EpCAM

The expression of two cell adhesion molecules, ECadherin and EpCAM, was upregulated by microRNA-96, and potential targets sites were identified in the coding sequences of their mRNAs. [Carcinogenesis] Abstract

Multiplex Profiling Identifies Clinically Relevant Signaling Proteins in an Isogenic Prostate Cancer Model of Radioresistance

Scientists analyzed the protein expression profiles of a previously generated isogenic 22Rv1 prostate cancer model of radioresistance using DigiWest multiplex protein profiling for a selection of 90 signaling proteins. [Sci Rep] Full Article

miR-133a-5p Inhibits Androgen Receptor (AR)-Induced Proliferation in Prostate Cancer Cells via Targeting fused in sarcoma (FUS) and AR

Investigators identified miRNAs that might target both FUS and AR to inhibit fused in sarcoma and androgen receptor expression. Based on TCGA data and the online tools UALCAN, Kaplan Meier-plotter, LncTar and miRWalk prediction, miR-133a-5p was selected. [Cancer Biol Ther] Abstract

Claudin-1 Upregulation Is Associated with Favorable Tumor Features and a Reduced Risk for Biochemical Recurrence in ERG-Positive Prostate Cancer

The authors evaluated the potential relevance of Claudin-1 expression in prostate cancer, a tissue microarray containing samples of 17,747 tumors with annotated clinico-pathological and molecular data was immunohistochemically analyzed for Claudin-1 expression. [World J Urol] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Androgen-Regulated MicroRNAs (AndroMiRs) as Novel Players in Adipogenesis

Existing knowledge about adipogenesis-related microRNAs and AndroMiRs is summarized, and putative cross-links are drawn, which are still prone to experimental validation. [Int J Mol Sci] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Anixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek^™ Prostate Cancer Study

Anixa Biosciences, Inc. announced its collaboration with Idaho Urologic Institute in the Cchek^™ early cancer detection study. Idaho Urologic Institute will provide patient samples for Anixa’s ongoing prostate cancer study, including support of clinical validation of Anixa’s Cchek^™ Prostate Cancer Confirmation test. [Anixa Biosciences, Inc.] Press Release

Myovant Sciences Announces 97% Response Rate in Positive Phase III HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

Myovant Sciences announced that the Phase III HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. [Myovant Sciences] Press Release

Science Funders Gamble on Grant Lotteries

Albert Einstein famously insisted that God does not play dice. But the Health Research Council of New Zealand does. The agency is one of a growing number of funders that award grants partly through random selection. [Nature News] Editorial

The Science Institutions Hiring Integrity Inspectors to Vet Their Papers

Some researchers have their manuscripts screened for errors before they go to journals. [Nature News] Editorial

Foreign Interference Fears Prompt Guidelines for Australian Universities

New guidelines will help Australian universities protect themselves against foreign interference, says the country’s government. The advice follows concerns that foreign groups or governments, such as the government of China, might be seeking to instigate campus activities that are against Australia’s interests. [Nature News] Editorial

NEW Noncoding RNAs: Mechanism, Function and Therapies
January 12-16, 2020
Whistler, British Columbia, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Tumor Metastasis (UPMC Hillman Cancer Center)

Assistant/Associate Faculty Position – Prostate Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Cancer Research (Max Delbrück Center for Molecular Medicine)

Senior Research Associate – Chemical Biology and Molecular Cell Biology of Cancer (Lancaster University)

Postdoctoral Position – Identification of RNA Risk Elements in Cancer Biology (University of Maryland Eastern Shore)

Clinical Research Scientist – Investigational Cancer Therapeutics (MD Anderson Cancer Center)

Tenure-Track Faculty Scientist Position – Radiation Oncology (New York University)

Postdoctoral Studentship – Genomics of Hereditary Prostate Cancer (University of Manchester)

Postdoctoral Researcher – Prostate Tumor Microenvironment (NorthShore University Health System)

Postdoctoral Researcher – Prostate Cancer (University of California, San Francisco)

Postdoctoral Scholar – Hormone Therapy Resistance in Prostate Cancer (Duke University Medical Center)

Assistant Professor – Biology of Genitourinary Cancers (University of Chicago)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.